A, Postoperative arterial events depending on different combinations of smoking and history of cardiovascular disease (CVD), defined as any of the following: hypertension (requiring medication), angina (in 30 days prior), dyspnea (at rest, on moderate exertion, or none), congestive heart failure (in 30 days prior), myocardial infarction (in 6 months prior), previous percutaneous coronary intervention, previous cardiac surgery, peripheral vascular disease (requiring revascularization, angioplasty, or amputation), rest pain, transient ischemic attack, or cerebrovascular accident without or with neurologic deficit. No CVD in the never smoker group constituted the reference group. B, Postoperative respiratory events according to different combinations of smoking and history of chronic obstructive pulmonary disease (COPD). No COPD in the never smoker group constituted the reference group.
The odds are adjusted for potential confounders and mediators described in Table 2 (ORadj-2), with never smokers as the reference group. Smoking history is divided into quintiles of pack-years. A, Thirty-day postoperative mortality. B, Arterial events. C, Respiratory events.
eTable 1. The American College of Surgeons National Surgical Quality Improvement Program
eTable 2. Criteria used to define 30-day postoperative outcomes
eTable 3. Association between smoking and 30-day postoperative outcomes (those with missing pack-year data counted as past smokers)
eTable 4. Association between smoking and 30-day postoperative outcomes (those with missing pack-year data excluded)
eTable 5. Association between smoking and 30-day postoperative outcomes stratifiedper patient demographics and surgical setting
eFigure. Adjusted odds ratios for 30-day postoperative venous events
Customize your JAMA Network experience by selecting one or more topics from the list below.
Musallam KM, Rosendaal FR, Zaatari G, Soweid A, Hoballah JJ, Sfeir PM, Zeineldine S, Tamim HM, Richards T, Spahn DR, Lotta LA, Peyvandi F, Jamali FR. Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. JAMA Surg. 2013;148(8):755–762. doi:10.1001/jamasurg.2013.2360
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The effects of smoking on postoperative outcomes in patients undergoing major surgery are not fully established. The association between smoking and adverse postoperative outcomes has been confirmed. Whether the associations are dose dependent or restricted to patients with smoking-related disease remains to be determined.
To evaluate the association between current and past smoking on the risk of postoperative mortality and vascular and respiratory events in patients undergoing major surgery.
Cohort study using the American College of Surgeons National Surgical Quality Improvement Program database. We obtained data on smoking history, perioperative risk factors, and 30-day postoperative outcomes. We assessed the effects of current and past smoking (>1 year prior) on postoperative outcomes after adjustment for potential confounders and effect mediators (eg, cardiovascular disease, chronic obstructive pulmonary disease, and cancer). We also determined whether the effects are dose dependent through analysis of pack-year quintiles.
Setting and Participants
A total of 607 558 adult patients undergoing major surgery in non–Veterans Affairs hospitals across the United States, Canada, Lebanon, and the United Arab Emirates during 2008 and 2009.
Main Outcomes and Measures
The primary outcome measure was 30-day postoperative mortality; secondary outcome measures included arterial events (myocardial infarction or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respiratory events (pneumonia, unplanned intubation, or ventilator requirement >48 hours).
The sample included 125 192 current (20.6%) and 78 763 past (13.0%) smokers. Increased odds of postoperative mortality were noted in current smokers only (odds ratio, 1.17 [95% CI, 1.10-1.24]). When we compared current and past smokers, the adjusted odds ratios were higher in the former for arterial events (1.65 [95% CI, 1.51-1.81] vs 1.20 [1.09-1.31], respectively) and respiratory events (1.45 [1.40-1.51] vs 1.13 [1.08-1.18], respectively). No effects on venous events were observed. The effects of smoking mediated through smoking-related disease were minimal. The increased adjusted odds of mortality in current smokers were evident from a smoking history of less than 10 pack-years, whereas the effects of smoking on arterial and respiratory events were incremental with increased pack-years.
Conclusions and Relevance
Smoking cessation at least 1 year before major surgery abolishes the increased risk of postoperative mortality and decreases the risk of arterial and respiratory events evident in current smokers. These findings should be carried forward to evaluate the value and cost-effectiveness of intervention in this setting. Our study should increase awareness of the detrimental effects of smoking—and the benefits of its cessation—on morbidity and mortality in the surgical setting.
Smoking remains a leading preventable cause of morbidity and mortality that is responsible for almost half a million deaths and about $200 billion in added costs for health care and lost productivity each year in the United States alone.1 The role of long-term tobacco dependence in increasing the risks of cancer and cardiovascular and pulmonary disease are well established. However, the effect of smoking on surgical outcomes has not been evaluated extensively. Until recently, most available clinical studies were small, reported data from a single surgical specialty, or evaluated only a few postoperative outcomes.2-12 However, 2 recent large multicenter studies13,14 confirmed the association between smoking and adverse postoperative outcomes. Turan and colleagues13 showed higher adjusted odds of postoperative mortality and major morbidity in 82 304 current smokers compared with those who never smoked (approximately 30% higher odds) using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). However, the authors did not evaluate the association between past smoking and the observed outcomes. Knowledge of whether smoking cessation modifies (reverses) the adverse effects of smoking remains crucial to promote smoking control measures. The effect of past smoking on postsurgical outcomes was evaluated recently through another large (n = 393 794) multicenter study using the Veterans Affairs Surgical Quality Improvement Program14 that reported that past smokers also have increased odds of 30-day postoperative mortality and major morbidity (approximately 20% higher odds). However, the authors did not adjust for several potential confounders that could have affected outcome rates and the patient’s decision to quit smoking and did not assess the effect of smoking that is not mediated by related disorders (eg, smoking leads to cardiac disease, which in turn leads to adverse postsurgical outcomes), and their study mainly involved men.14
With these previous reports in mind, the purpose of our study was to determine the effects of current as well as past smoking on the incidence of postoperative mortality and arterial, venous, and respiratory events using a large data set from the ACS NSQIP. We also aimed to evaluate whether the observed associations are dose dependent and to establish whether they are restricted to patients who had already acquired smoking-related disease.
This nested-cohort study used data from the ACS NSQIP database. Details of the ACS NSQIP (http://acsnsqip.org) have been recently described15 and are summarized in eTable in Supplement. The database is a validated outcomes registry designed to provide feedback to participating hospitals on 30-day risk-adjusted surgical mortality and morbidity.16,17 The database includes de-identified data on demographics, perioperative variables, and 30-day postoperative outcomes for adult patients undergoing major surgery in participating non–Veterans Affairs hospitals.16 Trained surgical clinical reviewers collect patient data on admission from the medical record, operative log, anesthesia record, interviews with the attending surgeon, and telephone interviews with the patient.16 Data quality is ensured through comprehensive training of the nurse reviewers, an interrater reliability audit of participating sites, regular conference calls, and an annual meeting.18
Included in this study were patients undergoing major surgery performed at participating ACS NSQIP medical centers during 2008 (271 368 patients from 211 sites) and 2009 (336 190 patients from 237 sites). In accordance with the American University of Beirut’s guidelines (which follow the US Code of Federal Regulations for the Protection of Human Subjects), institutional review board approval was not needed or sought for our analysis because the data were collected as part of a quality assurance activity.
Data on smoking history are included in the ACS NSQIP as part of the preoperative risk assessment. Patients were categorized into 3 groups on the basis of their smoking status. If the patient has smoked cigarettes in the year before admission for surgery, the patient was considered a current smoker. This definition excluded patients who smoked cigars or pipes or used chewing tobacco. If the patient had ever been a smoker, smoking history measured in pack-years for this patient (the number of packs of cigarettes smoked per day × the number of years the patient smoked) was also retrieved. In this study, patients with a record of pack-years who were not current smokers were categorized as past smokers. Patients who never smoked (ie, never smokers) were defined as patients who were classified as no for the current smoker variable and whose value for the pack-years variable was equal to 0 (325 434 patients [80.6% of never smokers]) or missing (78 169 [19.4% of never smokers]). We decided to classify those patients who had a no for current smoker and a missing for pack-years as never smokers because this approach was more conservative for the analysis of the relationship of smoking with surgical outcomes as determined by others.14 However, we also undertook 2 sensitivity analyses: one with such patients excluded and another with them considered past smokers.
Evaluated outcomes included 30-day postoperative mortality, arterial events (myocardial infarction or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respiratory events (pneumonia, unplanned intubation, or ventilator requirement >48 hours). The diagnoses were defined as described in eTable 2 in Supplement.
Descriptive data are given as mean (SD) or percentage. The primary study outcome was death within 30 days of the index surgery in the current and past smokers groups compared with the never smokers group. The secondary study outcome was the occurrence of arterial, venous, or respiratory events within 30 days of the index surgery in the current and past smokers groups compared with the never smokers group. We estimated unadjusted odds ratios (OR) and 95% confidence intervals for outcomes in the current and past smokers groups. We then constructed 2 multivariate logistic regression models for each outcome to adjust the association between smoking (current and past) and outcomes for 2 types of a priori–defined variables. In model 1 (ORadj-1), we adjusted for variables that are potential confounders but not mediators (ie, factors that could affect the decision of the patient to continue smoking, stop smoking, or never smoke but cannot be caused by smoking). In model 2 (ORadj-2), we adjusted for the variables included in model 1 plus variables that are potential mediators (ie, diseases that may have been caused by smoking). In such analyses, ORadj-1 would represent the true overall effect of current and past smoking on outcomes that is mediated and not mediated by smoking-related diseases; ORadj-2, the true effect of current and past smoking on outcomes that is not mediated by smoking-related diseases. The difference between ORadj-2 and ORadj-1 would represent the true effect of current and past smoking that is mediated by smoking-related diseases. We also stratified data from model 2 per demographics and different surgical settings.
To determine whether the observed effects of current and past smoking in model 2 are dose dependent, we also constructed multivariate logistic regression models with the current and past smokers groups divided into 5 equal quintiles according to pack-years of smoking. Data on pack-years were available for all past smokers (part of the definition) and for 84 338 current smokers (67.4%).
Data were nearly complete, with missing values only for body mass index (16 343 patients [2.7%]), which were imputed by the respective means of similar sex and age groups. All analyses were performed using commercially available software (SAS, version 9.2; SAS Institute, Inc).
We included data for 607 558 patients. Their mean age was 55.7 (SD, 17.1; range, 16-90) years, and 42.7% were men. A total of 125 192 patients (20.6%) were current smokers; 78 763 (13.0%), past smokers; and 403 603 (66.4%), never smokers. Table 1 compares demographics and preoperative medical histories among the 3 groups. Past smokers were oldest and most likely to be male or white. They were most likely to have an unfavorable American Society of Anesthesiologists class and had the highest prevalence of diabetes mellitus, obesity, hypertension, renal failure, chronic obstructive pulmonary disease, cardiovascular disease, and cancer (Table 1).
The crude rates (cumulative incidence) of postoperative outcomes plus the potential confounders and mediators for which we adjusted the models are summarized in Table 2. Current and past smokers had increased unadjusted odds of 30-day postoperative mortality and arterial and respiratory events compared with never smokers. However, on adjustment for potential confounders, only current smokers had increased odds of mortality after surgery (ORadj-1, 1.21 [95% CI, 1.14-1.28]). On further adjustment for potential mediators, the odds of mortality associated with current smoking dropped by only 4% (smoking-related disease effect), and patients maintained an increased odds of death (ORadj-2, 1.17 [95% CI, 1.10-1.24]). Moreover, on adjustment for potential confounders, the effect estimates of 30-day postoperative arterial and respiratory events were higher in current smokers (ORadj-1, 1.78 [95% CI, 1.63-1.93] and 1.53 [1.47-1.58], respectively) than in past smokers (1.28 [1.17-1.40] and 1.21 [1.17-1.27], respectively) when compared with never smokers. On further adjustment for potential mediators, a similar minimal effect of smoking-related disease on arterial and respiratory events was noted for current smokers (ORadj-2, 1.65 [95% CI, 1.51-1.81] and 1.45 [1.40-1.51], respectively) and past smokers (1.20 [1.09-1.31] and 1.13 [1.08-1.18], respectively). Current and past smokers did not have increased adjusted odds of 30-day venous events compared with never smokers (Table 2).
In the sensitivity analyses of patients who were not current smokers but had missing past pack-years data, results did not differ for the primary and secondary study outcomes whether they were considered past smokers rather than never smokers (eTable 3 in Supplement) or were excluded (eTable 4 in Supplement).
The increased adjusted odds of mortality and arterial and respiratory events in current smokers were generally noted across all age groups (mostly in those >40 years), in both sexes, in inpatients and outpatients, in those who underwent surgery with general or other types of anesthesia, in elective and emergency cases, and in various surgical subspecialties (eTable 5 in Supplement). We also stratified the analyses for postoperative arterial and respiratory events according to the presence of preoperative cardiovascular or chronic obstructive pulmonary disease, respectively (Figure 1)
When we considered history of cigarette smoking in pack-year data (dose-dependent effect), the increased adjusted odds of mortality in current smokers were evident in light (<10 pack-years) and heavy (≥50 pack-years) smokers. Past smokers did not have increased odds of mortality even with a cigarette smoking history of at least 50 pack-years (Figure 2A). The increased adjusted odds for arterial and respiratory events were incremental with increased pack-years, with current smokers generally having higher effect estimates across the whole range of pack-years of smoking. In fact, increased odds of arterial and respiratory events were noted only in past smokers who had smoking histories of at least 50 and at least 20 pack-years, respectively (Figure 2B and C). A similar trend was observed for venous events in current smokers, although the effect estimates remained minimal (eFigure in Supplement).
In this large multicenter study, we demonstrated that current but not past smoking is associated with an increased risk of mortality in patients undergoing major surgery. Moreover, although past smokers remain at risk of increased arterial and respiratory events after surgery, the effect is milder than that observed in current smokers. These findings encourage ongoing efforts to implement smoking cessation programs across various health care systems. Early intervention in heavy smokers is warranted, especially because the effect of smoking on postoperative arterial and respiratory morbidity seems to be dose dependent. However, because smokers with a cigarette smoking history of less than 10 pack-years are also at risk of postoperative death, recent and light smokers should also be targeted.
The prevalence of current smokers presenting for major surgery in our study (approximately 20%) is close to that reported by Turan et al13 but lower than that reported by Hawn et al14 (approximately 35%), who used data from the Veterans Affairs Surgical Quality Improvement Program involving mostly male veterans. However, the effects of current smoking on mortality and arterial, venous, and respiratory events echoed those reported by both studies, although they used more strict exclusion criteria (eg, excluding patients with the most severe disease, those undergoing cardiac surgery, or emergency cases).13,14 We chose to include all patients, apply extensive adjustment, and stratify outcomes per different patient groups. The adverse effects of current smoking were noted across several patient groups and surgical settings, although with varying effect estimates and uncertainties. This study should help to better target subpopulations who may benefit most from smoking cessation intervention trials.
In the study by Hawn et al,14 the authors found that past smokers remain at increased risk of mortality compared with never smokers and have similar or sometimes even higher odds of certain morbidities (eg, myocardial infarction) than current smokers when compared with never smokers. However, the authors in that study did not adjust the association for mediators, and the reported effect also includes that attributed to smoking-related disease. Moreover, only minimal adjustment for confounding was undertaken, which excluded some clinical conditions (not smoking related) that could cause the patient to stop smoking, while leaving him or her at higher risk of adverse outcomes (eg, obesity and diabetes mellitus). The key strengths of our study lie in the large number of patients and the reliable and comprehensive data collection tool of the ACS NSQIP, which provides more than 60 demographic and preoperative variables available for adjustment. Our study established that past smoking does not increase the risk of postoperative mortality and poses lower risks of arterial and respiratory events compared with those found in current smokers, which is in agreement with smaller studies on select populations.6,19
Our study demonstrates that smoking is associated with adverse postoperative outcomes irrespective of the presence of smoking-related disease (eg, cardiovascular disease, chronic obstructive pulmonary disease, and cancer). The effect of smoking on adverse postoperative outcomes mediated by smoking-related disease (the difference between ORadj-2 and ORadj-1) was minimal. This finding suggests that smoking may exert its effect on adverse postoperative outcomes through acute or subclinical chronic vascular and respiratory pathologic mechanisms. Smoking has acute exposure and chronic cumulative effects on pulmonary function. Toxins and particles in tobacco smoke activate the inflammatory system, ultimately leading to the destruction of alveoli and reduction of the surface area for gas exchange.20 Smoking impairs mucus transport, provokes goblet cell hyperplasia and thus causes stimulation of mucus overproduction,21 impairs pulmonary macrophage function,22 and increases bronchial reactivity by stimulation of airway inflammation.23 Moreover, animal studies show that exposure to tobacco smoke leads to an increased bacterial load and delayed bacterial clearance, demonstrating that cigarette smoke suppresses the respiratory antibacterial host defense and potentially increases the risk for pneumonia.24 The effects of smoking on vessel wall pathologic changes, progression of atherosclerosis, and thrombosis potential are numerous. Smoking increases oxidative stress and inflammation; promotes endothelial activation, dysfunction, and damage; alters the endothelium-mediated vascular tone control; increases hypercoagulability and platelet activation; and reduces fibrinolysis. A direct necrotic action on cardiomyocytes is also believed to exist.25 The contribution of smoking to venous thrombosis is still a matter of debate, and studies with a positive association reported effects smaller than those consistently observed in arterial thrombosis.26,27 Many of the smoking-induced effects on respiratory and vascular pathologic changes are at least partially reversible on cessation of exposure, usually within 1 year.28-31
One limitation in our study is that we could identify only past smokers who quit smoking less than 1 year before surgery (otherwise considered current smokers in the ACS NSQIP). This limitation will not permit any conclusions regarding the effects of smoking cessation when implemented closer to surgery (eg, at the time of the decision to undergo an elective procedure), but it does show that the benefits of smoking cessation on surgical outcomes may start appearing as soon as 1 year after cessation. This difference may have little importance in the individual setting but has relevance in the public health perspective. Studies in this direction had mixed results and depended on the surgical population and the timing and intensity of the intervention.19,32-39 In our multivariate analyses, we considered preoperative medical diseases that could be caused by smoking as mediators. However, these conditions may be confounders rather than mediators in some patients if smoking did not contribute to their causation but influenced the decision of the patient to continue or quit smoking. However, this confounding does not affect the main estimate in our study, ORadj-2, which represents the true and nonmediated effect of smoking.
Another potential limitation of this study was that we were unable to control for hospital effects owing to the absence of hospital identifiers in our data. Variability in hospital quality or in surgical strategy may have confounded the association between risk factors and outcome. Last, the ORadj of outcomes that we reported attributable to smoking might be regarded as of modest clinical significance because the crude 30-day outcome rates (cumulative incidence) in never smokers are low (eg, 0.3% for myocardial infarction). However, such adjusted increase in outcome rates in a large sample still means that a considerable number of patients could have acute adverse postoperative outcomes solely from the subclinical damaging effects of smoking (eg, 675 myocardial infarctions during the 2 years of the study). Moreover, our data included a wide variety of patients and surgical procedures from various surgical subspecialties with different crude outcome rates in never smokers (eTable 4 in Supplement), and the adjusted estimates of increased morbidity and mortality may be of higher clinical significance in certain patient populations or surgical procedures. Similarly, we reported adverse outcome rates applicable in a population with a case mix similar to that generated by the ACS NSQIP sampling strategy. If our findings are to be extrapolated to settings with higher adverse outcome rates, such relative increases would be of more apparent clinical significance.
Studies show that hospitals do not consistently provide smoking cessation services to their hospitalized patients, and in most cases these services are restricted to adults admitted for acute myocardial infarction, congestive heart failure, or pneumonia.1 Our study should increase awareness of the detrimental effects of smoking—and the benefits of its cessation—on morbidity and mortality in the surgical setting. Surgical teams should thus be more involved in the ongoing efforts to optimize measures for smoking control. Surgery provides a teachable environment for smoking cessation. Unlike the long-term consequences of smoking, the acute consequences of smoking on patients’ postoperative outcomes can provide a strong motive for quitting.40 The cost-effectiveness of such interventions warrants further study. Finally, the effects of other forms of tobacco smoking, such as cigars, pipers, and water pipes, on surgical outcomes merit evaluation.
Corresponding Author: Faek R. Jamali, MD, Department of Surgery, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107 2020, Lebanon (email@example.com).
Accepted for Publication: January 9, 2013.
Published Online: June 19, 2013. doi:10.1001/jamasurg.2013.2360.
Author Contributions: Drs Musallam and Hoballah had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors gave final approval of the manuscript for submission.
Study concept and design: Musallam, Richards, and Jamali.
Acquisition of data: Soweid, Hoballah, Sfeir, and Zeineldine.
Analysis and interpretation of data: Musallam, Rosendaal, Zaatari, Tamim, Spahn, Lotta, Peyvandi, and Jamali.
Drafting of the manuscript: Musallam.
Critical revision of the manuscript for important intellectual content: Rosendaal, Zaatari, Soweid, Hoballah, Sfeir, Zeineldine, Tamim, Richards, Spahn, Lotta, Peyvandi, and Jamali.
Statistical analysis: Musallam, Rosendaal, and Jamali.
Administrative, technical, and material support: Hoballah and Jamali.
Study supervision: Richards and Jamali.
Conflict of Interest Disclosures: None reported.
Disclaimer: The ACS NSQIP and the participating hospitals are the source of data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.